Objective: To review the oral and injectable pharmacologic treatment options for type 2 diabetes. Data Sources: A literature search was conducted using PubMed electronic database for studies published in English between 1993 and September 2014. Search terms included diabetes mellitus, type 2 diabetes, and the individual name for each antidiabetic medication reviewed. In addition, manual searches were performed for cross-references from publications. Package inserts, United States Food and Drug Administration (FDA) Web site, Institute for Safe Medication Practices Web site, American Diabetes Association Web site and scientific session poster presentations, and individual drug company Web pages were also reviewed. Study Selection and Data Extraction: This review focused on information elucidated over the past 10 years to assist prescribers in choosing optimal therapy based on individual patient characteristics. Studies leading to the approval of or raising safety concerns for the antidiabetic medications reviewed in this article were included. Data Synthesis: In the past 10 years, there have been 4 novel oral antidiabetic medication classes and 10 new injectable agents and insulin products approved by the FDA for the treatment of type 2 diabetes as well as new information regarding the safety and use of several older antidiabetic medication classes. The distinctions were reviewed for each individual agent, and a comparison was completed if there was more than one agent in a particular therapeutic class. Using current information available, select investigational agents in phase III trials or with a pending new drug application were highlighted. Conclusion: There are now 9 distinct oral pharmacologic classes and a variety of insulin and noninsulin injectable medications available for the treatment of type 2 diabetes. Metformin remains the first-line treatment option for most patients. When considering options for alternative or additional treatment, prescribers must weigh the benefits and risks using individual patient characteristics.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
2.
PatelAMacMahonSChalmersJ; The ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572. doi:10.1056/NEJMoa0802987.
3.
Ismail-BeigiFCravenTBanerjiMA. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet. 2010;376:419-430. doi:10.1016/S0140-6736(10)60576-4.
4.
DuckworthWAbrairaCMortizW. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139. doi:10.1056/NEJMoa0808431.
SymlinPen (pramlintide) [product information]. Wilmington, DE: AstraZeneca; 2014.
10.
HollanderPALevyPFinemanMS. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26:784-790.
11.
HollanderPRatnerRFinemanM. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003;5:408-414.
12.
KarlDPhilis-TsimikasADarsowT. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther. 2007;9:191-199.
13.
RiddleMFriasJZhangB. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30:2794-2799.
14.
PencekRRoddyTPetersY. Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study. Diabetes Obes Metab. 2010;12:548-551. doi:10.1111/j.1463-1326.2010.01201.x.
15.
HolstJJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439. doi:10.1152/physrev.00034.2006.
Tanzeum (albiglutide) injection [product information]. Wilmington, DE: GlaxoSmithKline LLC; 2014.
20.
BarringtonPChienCYShowalterHDHCuiSTibaldiF. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide 1-analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:426-433. doi:10.1111/j.1463-1326.2011.01364.x.
21.
WyshamCBlevinsTArakakiR. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159-2167. doi:10.2337/dc13-2760.
22.
UmpierrezGTofé PovedanoSPérez ManghiFShurzinskeLPechtnerV. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168-2176. doi:10.2337/dc13-2759.
23.
NauckMWeinstockRSUmpierrezGEGuerciBSkrivanekZMilicevicZ. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149-2158. doi:10.2337/dc13-2761.
24.
MorettoTJMiltonDRRidgeTD. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448-1460. doi:10.1016/j/clinthera.2008.08.006.
25.
GarberAHenryRRatnerR. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481. doi:10.1016/S0140-6736(08)61246-5.
26.
Russell-JonesDCuddihyRMHanfeldM. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4). Diabetes Care. 2012;35:252-258. doi:10.2337/dc11-1107/-/DC1.
27.
ReinhardtRNauckMAStewartM. HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia2013;56(Suppl 1):S360.
28.
DeFronzoRARatnerREHanJKimDDFinemanMSBaronAD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
29.
BuseJBHenryRRHanJKimDDFinemanMSBaronAD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
30.
KendallDMRiddleMCRosenstockJ. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
31.
ZinmanBHoogwerdBJGarciaSD. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med. 2007;146:477-485.
32.
HeineRJVan GaalLFJohnsDMihmMJWidelMHBrodowsRG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005;143:559-569.
33.
BarnettAHBurgerJJohnsD. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333-2348. doi:10.1016/j.clinthera.2007.11.006.
34.
MarreMShawJBrandleM. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with added rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278. doi:10.1111/j.1464-5491.2009.0266.x.
35.
NauckMFridAHermansenK. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care. 2009;32:84-90. doi:10.2337/dc08-1355.
36.
Russell-JonesDVaagASchmitzO. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046-2055. doi:10.1007/s00125-009-1472-y.
37.
ZinmanBGerichJBuseJB. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32:1224-1230. doi:10.2337/dc08-2124.
38.
BuseJBRosenstockJSestiG. Liraglutide once weekly versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47. doi:10.1016/S0140-6736(09)60659.
39.
PratleyRENauckMBaileyT. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-1456. doi:10.1016/S0140-6736(10)60307-8.
40.
BuseJBNauckMForstT. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117-124. doi:10.1016/S0140-6736(12)61267-7.
41.
DruckerDJBuseJBTaylorK. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240-1250. doi:10.1016/S0140-6736(08)61206-4.
42.
BergenstalRMWyshamCMacConellL. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431-439. doi:10.1016/S0140-636(10)60590-9.
43.
DiamantMVan GaalLStranksS. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:223-243. doi:10.1016/S0140-6736(10)60406-0.
44.
BlevinsTPullmanJMalloyJ. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301-1310. doi:10.1210/jc/2010-2081.
45.
KimDMacConellLZhuangD. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487-1493.
46.
AhrenBJohnsonSStewartM. HARMONY 3: 104-week randomized, double blind, placebo-and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37:2141-2148. doi:10.2337/dc14-0024.
47.
PratleyRStewartMCirkelD. HARMONY 4: 52-week efficacy of albiglutide vs insulin glargine in patients with type 2 diabetes mellitus. Diabetologia2013;56(Suppl 1):S360.
48.
StewartMHomePYangFPerryCCarrMC. 52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: HARMONY 5 study. Diabetologia2013;56(Suppl 1):S361.
49.
PratleyRENauckMABarnettAH. Once-weekly albiglutide verses once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289-297. doi:10.1016/S2213-8587(13)70214-6.
50.
WoodwardHAndersonA. Once-weekly albiglutide in the management of type 2 diabetes: patient considerations. Patient Prefer Adherence. 2014;8:789-803. doi:10.2147/PPA.SS3075.
51.
LeiterLCarrMStewardM. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37:2723-2730. doi:10.2337/dc13-2855.
52.
GiorginoFBenroubiMSunJHZimmermannAGPechtnerV. Efficacy and safety of once-weekly dulaglutide vs. insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2). Paper presented at: 74th Scientific Session American Diabetes Association; June 13-17, 2014; San Francisco, CA.
53.
RosenstockJFonsecaVGrossJ. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice daily prandial insulin lispro. Diabetes Care. 2014;37:2317-2325. doi:10.2337/dc14-0001.
54.
NauckMADuranSKimD. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259-267. doi:10.1007/s00125-006-0510-2.
55.
BuseJBDruckerDJTaylorKL. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33:1255-1261. doi:10.2337/dc09-1914.
56.
DunganKMPovedanoSTForstT. Once-weekly dulaglutide versus once-daily liraglutide in metformin- treated patients with type 2 diabetes (AWARD-6): a randomized, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349-1357. doi:10.1016/S0140-6736(14)60976-4.
57.
RosenstockJReuschJBushMYangFStewartM. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes. Diabetes Care. 2009;32:1880-1886. doi:10.2337/dc09-0366.
58.
NauckMFridAHermansenK. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013;15:204-212. doi:10.1111/dom.12012.
59.
KlonoffDCBuseJBNielsenLL. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-286. doi:10.1185/030079907X253870.
60.
BuseJBSestiGSchmidtWE. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33:1300-1303. doi:10.2337/dc09-2260.
61.
TaylorKGurneyKHanJPencekRWalshBTrautmannM. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011;11:9. doi:10.118/1472-6823-11-9.
62.
MacConellLPencekRLiYMaggsDPorterL. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31-41. doi:10.2147/DMSO.S35801.
63.
DiamantMVan GaalLStranksS. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care. 2012;35:683-689. doi:10.2337/dc11-1233.
64.
ElashoffMMatveyenkoAVGierBElashoffRButlerPC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-156. doi:10.1053/j.gastro.2011.02.018.
FDA Drug Safety Communication. FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm. Accessed March 16, 2014.
67.
GirmanCJKouTDCaiB. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab. 2010;12:766-771. doi:10.1111/j.1463-1326.2010.01231.x.
EganABlindEDunderK. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370:794-797. doi:10.1056/NEJMp1314078.
70.
StrangesPKhanderiaU. Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf. 2014;3:185-201. doi:10.1177/2042098612454290
71.
MonamiMCremascoFLamannaC. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011;2011:215764. doi:10.1155/2011/215764.
72.
SeufertJGallwitzB. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab. 2014;16:673-688. doi:10.1111/dom.12251.
73.
MonamiMDicembriniINardiniCFiordelliIMannucciE. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:38-47. doi:10.1111/dom.12175.
74.
MarsoSPPoulterNRNissenSE. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166:823-830. doi:10.1016.j.ahj.2013.07.012.
75.
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. http://clinicaltrials.gov/show/NCT01144338. Accessed March 11, 2014.
PlankJBodenlenzMSinnerF. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107-1112.
87.
HollanderPCooperJBregnhøiJPedersenCB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30:1976-1987. doi:10.1016/j.clinthera.2008.11.001.
88.
RaskinPGylvinTWengWChaykinL. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25:542-548. doi:10.1002/dmrr.989.
89.
RosenstockJDaviesMHomePDLarsenJKoenenCSchernthanerG. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408-416. doi:10.1007/s00125-007-0911-x.
90.
SwinnenSGDainMPAronsonR. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33:1176-1178. doi:10.2337/dc09-2294.
91.
SwinnenSGSimonACHollemanFHowkstraJBDevriesJH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;(6):CD006383. doi:10.1002/14651858.CD006383.pub2.
92.
FakhouryWLockhartIKotchieRWAggrenMLeRunC. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Pharmacology. 2008;82:156-163. doi:10.1159/000149569.
93.
MäkimattilaSNikkiläKYki-JärvinenH. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia. 1999;42:406-412.
94.
SalléARyanMGuilloteauGBouhanickBBerrutGRitzP. “Glucose control-related” and “non-glucose control-related” effects of insulin weight gain in newly insulin-treated type 2 diabetic patients. Br J Nutr. 2005;96:931-937.
95.
ZibIRaskinP. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab. 2006;8:611-620.
96.
HemkensLGGrouvenUBenderR. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732-1744. doi:10.1007/s00125-009-1418-4.
97.
JonassonJMLjungRTalbäckMHaglundBGudbjörnsdòttirSSteineckG. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745-1754. doi:10.1007/s00125-009-1444-2.
98.
CurrieCJPooleCDGaleEA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766-1777. doi:10.1007/s00125-009-1440-6.
99.
FagotJPBlotièrePORicordeauPWeillAAllaFAllemandH. Does insulin glargine increase the risk of cancer compared with other basal insulins? A French nationwide cohort study based on national administrative databases. Diabetes Care. 2013;36:294-301. doi:10.2337/dc12-0506.
100.
NathanDMBuseJBDavidsonMB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of Diabetes. Diabetes Care. 2009;32:193-203. doi:10.2337/dc08-9025.
101.
Food and Drug Administration. FDA drug safety communication: update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. http://www.fda.gov/Drugs/DrugSafety/ucm239376.htm. Accessed February 24, 2014.
RiddleMCRosenstockJGerichJ; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
104.
HamatyM. Insulin treatment for type 2 diabetes: when to start, which to use. Cleve Clin J Med. 2011;78:332-342. doi:10.3949/ccjm.78a.10051.
105.
PetznickA. Insulin management of type 2 diabetes mellitus. Am Fam Physician. 2011;84:183-190.
106.
HamannAMatthealSRosakCSilvestreL; HOW901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2003;26:1738-1744.
107.
Massi BenedettiMHumburgEDresslerAZiemenM. A one-year, randomized, multicenter trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res. 2003;35:189-196.
108.
Yki-JärvinenHKauppinen-MäkelinRTiikkainenM. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442-451.
109.
FritscheASchweitzerMAHäringHU; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2003;138:952-959.
110.
RosenstockJSchwartzSLClarkCMParkGDDonleyDWEdwardsMB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOW 901) and NPH insulin. Diabetes Care. 2001;24:631-636.
111.
EliaschewitzFGCalvoCValbuenaH. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res. 2006;37:495-501.
112.
HomePDBolliGBMathieuC. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes [published online June24, 2014]. Diabetes Obes Metab. doi:10.1111/dom.12329.
113.
MeneghiniLKoenenCWengWSelamJL. The use of a simplified self-titration dosing guidelines (303 algorithm) for insulin detemir in patients with type 2 diabetes: results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9:902-913.
114.
GersteinHCYaleJFHarrisSBIssaMStewartJADempseyE. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment) Study. Diabet Med. 2006;23:736-742.
115.
DaviesMStormsFShutlerSBianchi-BiscayMGomisR; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282-1288.
116.
Yki-JärvinenHJuurinenLAlvarssonM. Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007;30:1364-1369.
117.
HermansenKDaviesMDerezinskiTMartinez RavenGClausonPHomeP. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
118.
JankaHUPlemeGRiddleMCKliebe-FrischCSchweitzerMAYki-JärvinenH. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-259.
119.
KennedyLHermanWHStrangePHarriesA; GOAL A1C Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HgA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29:1-8.
120.
HolmanRRThorneKIFarmerAJ. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-1730.
121.
HolmannRRFarmerAJDaviesMJ. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736-1747. doi:10.1056/NEJMoa0905479.
122.
BergenstalRMJohnsonMPowersMA. Adjustment to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin gluisine. Diabetes Care. 2008;31:1305-1310. doi:10.2337/dc07-2137.
123.
KawamoriREliaschewitzFGTakayamaHHayashidaCY. Efficacy of insulin glargine and glimiperide in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;79:97-102.
124.
BlondeLMerilainenMKarweVRaskinP; TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets. The TITRATE study. Diabetes Obes Metab. 2009;11:623-631. doi:10.1111/j.1463-1326.2009.01060.x.
125.
LieblAPragerRBinzK. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diabetes Obes Metab. 2009;11:45-52. doi:10.1111/j.1463-1326.2008.00915.x.
126.
ArnoldsSDellwegSClairJ. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33:1509-1515. doi:10.2337/dc09-2191.
127.
StrangeP. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol. 2007;1:540-548.
128.
RosenstockJFonsecaVSchinzelSDainMPMullinsPRiddleM. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. J Diabetes Complications. 2014;28:742-749. doi:10.1016/j.jdiacomp.2014.04.003.
129.
SiegmundTWeberSBlankenfeldHOeffnerASchumm-DraegerPM. Comparison of insulin glargine versus NPH insulin in people with type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes. 2007;115:349-353.
130.
HaakTTiengoADraegerESuntumMWaldhuslW. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
131.
RaslováKBogoevMRazILethGGallMAHâncuN. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193-201.
132.
SinghSRAhmadFLalAYuCBaiZBennettH. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009;180:385-397. doi:10.1503/cmaj.081041.
133.
WaughNCumminsERoyleP. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1-248. doi:10.3310/hta14360.
134.
HorvathKJeitlerKBergholdA. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD005613.
135.
De La PenaARiddleMMorrowLA. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34:2496-2501. doi:10.2337/dc11-0721.
136.
JørgensenKHHansenAKBuschardK. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract. 2000;50:161-167.
137.
LaneWSCochranEKJacksonJA. High-dose insulin therapy: is it time for U-500 insulin?Endocr Pract. 2009;15:71-79.
138.
CochranEGordenP. Use of U-500 insulin in the treatment of severe insulin resistance. Insulin. 2008;3:211-218.
139.
CochranEMussoCGordenP. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28:1240-1244.
140.
DavidsonMBNavarMDEcheverryDDurnaP. U-500 regular insulin clinical experience and pharmacokinetics in obese, severely insulin resistant type 2 diabetic patients. Diabetes Care. 2010;33:281-283. doi:10.2337/dc09-1490.
141.
BallaniPTranMTNavarMDDavidsonMB. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care. 2006;2:2504-2505.
142.
NealJM. Analysis of effectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy. Endocr Pract. 2005;11:305-307.
143.
DaileyAMWilliamsSTanejaDTannockLR. Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract. 2010;88:259-264. doi:10.1016/j.diabres.2010.02.012.
144.
QuinnSLLansangMCMinaD. Safety and effectiveness of U-500 insulin therapy in patients with insulin-resistant type 2 diabetes mellitus. Pharmacotherapy. 2011;31:695-702. doi:10.1592/phco.31.7.695.
145.
NayyarVJarviaJLawrenceI. Long-term follow up of patients on U-500 insulin: a case series. Pract Diabetes Int. 2010;27:194-197. doi:10.1002/pdi.1480.
146.
WafaWSKhanMI. Use of U-500 regular insulin in type 2 diabetes. Diabetes Care. 2006;29:2175-2176.
147.
ReutrakulAWroblewskiKBrownRL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol. 2012;6:412-420.
148.
LaneWSWeinribSLRappaportJMHaleCBFarmerLKLaneRS. The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes. Endocr Pract. 2013;19:196-201. doi:10.4158/EP12226.OR.
149.
AndresJClementsJN. A practical guide to concentrated insulin for pharmacists [published online January9, 2014]. J Pharm Pract. doi:10.1177/0897190013516505.
GargRJohnstonVMcNallyPGDaviesMJLawrenceIG. U-500 insulin: why, when and how to use in clinical practice. Diabetes Metab Res Rev. 2007;23:265-268.
152.
DaileyAMTannockLR. Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus. Curr Diab Rep. 2011;11:77-82. doi:10.1007/s11892-010-0167-6.
153.
EbyELWangPCurtisBH. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. J Med Econ. 2013;16:529-538. doi:10.3111/13696998.2013.772059.
154.
EbyELZagarAJWangP. Healthcare costs and adherence associated with human regular U-500 versus high-dose U-100 insulin in patients with diabetes. Endocr Pract. 2014;20:663-670. doi:10.4158/EP13407.OR.
155.
BretzelRGEckhardMLandgrafWOwensDRLinnT. Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents. Diabetes Care. 2009;32(suppl 2):S260-S265. doi:10.2337/dc09-S319.
156.
AbrahamsonMJPetersA. Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapy. Ann Med. 2012;44:836-846. doi:10.3109/07853890.2012.699715.
157.
OwensDRvan SchalkwykCSmithP. Algorithm for introduction of rapid-acting insulin analogues in patients with type 2 diabetes on basal insulin therapy. Pract Diab Int. 2009;26:70-77.
158.
American Association of Clinical Endocrinologists. Association of Clinical Endocrinologists medical guidelines for the management of diabetes: AACE Comprehensive Diabetes Management Algorithm. Endocr Pract. 2013;19:333. doi:10.4158/EP13210.
159.
DewittDEDugdaleD. Using new insulin strategies in the outpatient treatment of diabetes. JAMA. 2003;17:2266-2269.
160.
MorelloCM. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med. 2011;4:827-835. doi:10.2147/IJGM.S26889.
161.
MudaliarSRLindbergFAJoyceM. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22:1501-1506.
162.
PerrielloGPampanelliSPorcellatiF. Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabet Med. 2005;22:606-611.
163.
DaveyPGraingerDMacMillanJRajanNAristidesMGliksmanM. Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis. Clin Ther. 1997;19:656-674.
164.
RossSAZinmanBCamposRVStrackT. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med. 2001;24:292-298.
165.
DaileyGRosenstockJMosesRWaysK. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care. 2004;27:2363-2368.
166.
PlankJSiebenhoferABerholdA. Short acting insulin analogues versus regular insulin in patient with diabetes mellitus. Cochrane Database Syst Rev. 2006;(2):CD003287.
167.
RaveKPotockaEHeinemannL. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11:715-720. doi:10.1111/j.1463-1326.2009.01039.x.
168.
RosenstockJLorberDLGnudiL. Prandial inhaled insulin plus basal insulin glargine versus twice biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375:2244-2253. doi:10.1016/S0140-6736(10)60632-0.
169.
RaskinPHellerSHonkaM. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab. 2012;14:163-173. doi:10.1111/j.1463-1326.2011.01500.
OwensDR. Stepwise intensification of insulin therapy in type 2 diabetes management: exploring the concept of the basal-plus approach in clinical practice. Diabet Med. 2013;30:276-288. doi:10.1111/dme.12019.
172.
Ampudia-BlascoFJRossettiPAscasoJF. Basal plus basal-bolus approach in type 2 diabetes. Diabetes Technol Ther. 2011;13(suppl):S75-S83. doi:10.1089/dia.2011.0001.
GiuglianoDChiodiniPMaiorinoMICerielloABellastellaGEspositoK. Efficacy of insulin analogs in achieving the hemoglobin A1c target < 7% in type 2 diabetes. Diabetes Care. 2011;34:510-517. doi:10.2337/dc10-1710.
178.
HeiseTNosekLBottcherSGHastrupHHaahrH. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944-950. doi:10.1111/j.1463-1326.2012.01638.
179.
RodbardHWCariouBZinmanB. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with type 2 diabetes: a 2-year randomized treat to target trial. Diabet Med. 2013;11:1298-1304. doi:10.1111/dme.12303.
JaxTHeiseTDahmenR. New insulin glargine formulation has a flat and prolonged steady state profile in subjects with type 1 diabetes. Diabetologia. 2013;56(suppl 1):A1029.
182.
RiddleMCBolliGBZiemenMMuehlen-BartmerIBizetFHomePD. New insulin glargine formulation: glucose control and hypoglycaemia in people with type 2 diabetes using basal and mealtime insulin (EDITION 1). Diabetologia. 2013;56(suppl 1):A220.
183.
RitzelRRouseelRBolliGBVinetLYki-JarvinenH. New insulin glargine 300 U/ml: glycemic control and hypoglycemia in a meta-analysis of phase 3a EDITION clinical trials in people with T2DM. Paper presented at: 74th Scientific Session, American Diabetes Association; June 13-17, 2014; San Fransisco, CA.
InzucchiSEBergenstalRMBuseJB. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149. doi: 10.2337/dc14-2441.
